BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 21624553)

  • 21. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
    Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus- and zotarolimus-eluting stents for bare metal stent in-stent restenosis treatment: a prospective study.
    Toutouzas K; Patsa C; Tsiamis E; Tsioufis C; Spanos A; Stefanadi E; Tentolouris C; Stefanadis C
    J Interv Cardiol; 2008 Oct; 21(5):388-94. PubMed ID: 18705639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
    Räber L; Magro M; Stefanini GG; Kalesan B; van Domburg RT; Onuma Y; Wenaweser P; Daemen J; Meier B; Jüni P; Serruys PW; Windecker S
    Circulation; 2012 Mar; 125(9):1110-21. PubMed ID: 22302840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials.
    Cassese S; Piccolo R; Galasso G; De Rosa R; Piscione F
    Int J Cardiol; 2011 Jul; 150(1):84-9. PubMed ID: 21315461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
    Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
    Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).
    Hanna NN; Gaglia MA; Torguson R; Ben-Dor I; Gonzalez MA; Collins SD; Syed AI; Maluenda G; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2010 Aug; 106(4):504-10. PubMed ID: 20691308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions.
    Kim YH; Park SW; Lee CW; Hong MK; Gwon HC; Jang Y; Lee MM; Koo BK; Oh DJ; Seung KB; Tahk SJ; Yoon J; Park SJ
    Catheter Cardiovasc Interv; 2006 Feb; 67(2):181-7. PubMed ID: 16400663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
    Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
    EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
    Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
    Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial.
    Park KW; Chae IH; Lim DS; Han KR; Yang HM; Lee HY; Kang HJ; Koo BK; Ahn T; Yoon JH; Jeong MH; Hong TJ; Chung WY; Jo SH; Choi YJ; Hur SH; Kwon HM; Jeon DW; Kim BO; Park SH; Lee NH; Jeon HK; Gwon HC; Jang YS; Kim HS
    J Am Coll Cardiol; 2011 Oct; 58(18):1844-54. PubMed ID: 22018294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
    Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
    Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Percutaneous coronary intervention with second-generation paclitaxel-eluting stents versus everolimus-eluting stents in United States contemporary practice (REWARDS TLX Trial).
    Waksman R; Ghali M; Goodroe R; Ryan T; Turco M; Ring M; McGarry T; Dobies D; Shammas N; Steinberg DH; Swymelar S; Kaneshige K; Torguson R
    Am J Cardiol; 2012 Oct; 110(8):1119-24. PubMed ID: 22762711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.
    Onuma Y; Miquel-Hebert K; Serruys PW;
    EuroIntervention; 2013 Jan; 8(9):1047-51. PubMed ID: 23339811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
    Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.